局部性硬皮症中的固酶-4抑制:局部性罗夫米拉斯的病例系列
Ghassan Barnawi1, Alexandra Carla Bobica2, Hessah BinJadeed1
1Division of Dermatology, Department of Medicine, McGill University Health Centre, Montréal, QC, Canada.
SAGE open medical case reports
|December 19, 2025
概括
局部使用的罗夫卢米拉斯特奶油显著改善了三名对其他治疗无反应的患者的严重局部性硬皮病 (形状). 这种非免疫抑制疗法显示出快速的抗炎和抗纤维性作用,没有报告的副作用.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 局部性硬化皮质 (形状性皮质) 是一种慢性纤维化皮肤疾病,治疗选择有限.
- 现有的疗法往往不适合老年人,免疫力低下或全身不耐受的患者.
研究的目的:
- 为了评估局部罗米拉斯特0.3%奶油在严重的,治疗不耐药的局部性硬质皮质硬化症中的疗效和安全性.
主要方法:
- 三名患有重症局部性硬化症的成年患者的病例系列.
- 在遮蔽下使用局部罗夫米拉斯特0.3%奶油进行治疗.
- 临床评估使用验证的得分 (局部化结核病活动指数,医生的全球评估).
主要成果:
- 这三名患者在6-12周内均表现出快速且实质性的临床改善.
- 观察到明显减少炎症活动,疼痛和皮肤硬化.
- 在治疗期间没有报告任何不良事件.
结论:
- 局部使用0.3%的罗米拉斯特奶油可能是局部性硬化症的耐受性良好,非免疫抑制的选择.
- 固-4抑制显示出作为治疗策略的潜力,用于纤维化皮肤疾病,如morphea.
- 需要进一步的研究,以在更大的研究中证实这些发现.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
529
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
529
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K